TGFB1 and breast carcinoma: Based on this finding and those that indicate that TGFβ blockade can prevent metastatic progression to bone, we conclude that treatment with anti-TGFβ antibody 1D11 may have a two-fold benefit for the breast cancer patients by both inhibiting cancer progression and preventing bone loss.